Evidence map›Paper›PMID 41579185›Full record

ArticleSurgery today2026

The prognostic impact of primary tumor resection or stoma construction followed by systemic chemotherapy for stage IV colorectal cancer: A Japanese, multicenter study.

Mariko Yamashita, Keisuke Noda, Tetsuro Tominaga, Yuma Takamura, Hiroki Katayama, Shintaro Hashimoto, Shoko Tei, Rika Ono, Mitsutoshi Ishii, Makoto Hisanaga and 7 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Surgery today, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Mariko YamashitaDivision of Surgical Oncology, Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852- 8501, Japan.
Keisuke NodaDivision of Surgical Oncology, Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852- 8501, Japan.
Tetsuro TominagaDivision of Surgical Oncology, Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852- 8501, Japan.
Yuma TakamuraDivision of Surgical Oncology, Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852- 8501, Japan.
Hiroki KatayamaDivision of Surgical Oncology, Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852- 8501, Japan.
Shintaro HashimotoDivision of Surgical Oncology, Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852- 8501, Japan.
Shoko TeiDivision of Surgical Oncology, Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852- 8501, Japan.
Rika OnoDepartment of Surgery, Sasebo City General Hospital, 9-3 Hirasemachi, Nagasaki, 857-8511, Japan.
Mitsutoshi IshiiDepartment of Surgery, Sasebo City General Hospital, 9-3 Hirasemachi, Nagasaki, 857-8511, Japan.
Makoto HisanagaDepartment of Surgery, Sasebo City General Hospital, 9-3 Hirasemachi, Nagasaki, 857-8511, Japan.
Kaido OishiDepartment of Surgery, National Hospital Organization Nagasaki Medical Center, 1-1001-1, Omura, Nagasaki, 856-8562, Japan.
Masaaki MoriyamaDepartment of Surgery, Isahaya General Hospital, 24-1, Isahaya, Nagasaki, 854-8501, Japan.
Fumitake UchidaDepartment of Surgery, Ureshino Medical Center, 4279-3 Ko, Ureshinomachi, Shimojuku, Ureshino, 843-0393, Oaza, Saga, Japan.
Toshio ShiraishiDepartment of Surgery, Saiseikai Nagasaki Hospital, 2-5-1 Katafuchi, Nagasaki, 850-0003, Japan.
Masaki KunizakiDepartment of Surgery, Saseno Chuo Hospital, 15 Yamatocho, Sasebo, 857- 1195, Japan.
Takashi NonakaDivision of Surgical Oncology, Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852- 8501, Japan. tnonaka@nagasaki-u.ac.jp.
Keitaro MatsumotoDivision of Surgical Oncology, Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852- 8501, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeFew reports have so far compared cases of Stage IV colorectal cancer in which primary tumor resection or stoma creation was performed prior to systemic chemotherapy.

methodsWe retrospectively reviewed 246 patients with clinical Stage IV colorectal cancer who underwent surgery followed by systemic chemotherapy. The patients were divided into two groups: those who underwent only stoma creation (stoma group, n = 62) and those who underwent primary tumor resection (resection group, n = 164).

resultsThe stoma group had more male patients (stoma group vs. resection group, 74.2% vs. 54.8%; p = 0.009), more comorbidities (88.7% vs. 73.2%, p = 0.012), and more rectal tumors (38.7% vs. 11.0%; p < 0.001); after propensity score matching, no differences were seen, but shorter operation time (110 vs. 174 min; p < 0.001), less blood loss (5 vs. 11 mL; p < 0.001), longer hospital stay (19 vs. 14 days; p = 0.003), and a shorter duration from surgery to first chemotherapy (27 vs. 35 days; p < 0.001) were seen in the stoma group, with a better overall survival in the resection group (p = 0.036).

conclusionPrimary resection of stage IV colorectal cancer is associated with a better prognosis. However, highly invasive surgery may cause postoperative complications and a poor prognosis; therefore, careful consideration of its appropriateness is necessary.

Indexed as

Colorectal NeoplasmsSurgical StomasAgedColorectal Surgical ProceduresCombined Modality TherapyEast Asian PeopleFemaleHumansJapanLength of StayMaleMiddle AgedNeoplasm StagingOperative TimePrognosisRetrospective StudiesColorectal cancerLaparoscopic surgeryLife-threatening complication

Identifiers

PMID41579185

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.